Europe Frontotemporal Dementia Market By Drug Class Type (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others), By Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Country, Competition, Forecast & Opportunities, 2028

Europe frontotemporal dementia market is expected to witness significant growth during the forecast period, 2024-2028. Growing prevalence of dementia along with growing aging population in the region is anticipated to facilitate the growth of the market. The gradual increase in the number of new cases of dementia registered directly every year are strengthening the growth of the frontotemporal dementia market. Moreover, the rising fundings provided by government as well as by the several non-profit organizations for the target disease care, support, and R&D activities to develop new drug are the major factor propelling the growth of the market. Furthermore, the advent of novel Frontotemporal dementia therapies as well as new diagnosing biomarkers are projected to augment the growth of the market. Rising number of clinical trials in the region are propelling the growth of the market.

Frontotemporal dementia refers to a group of uncommon brain disorders that primarily affect the frontal and temporal lobes of the brain. These areas of the brain are generally associated with personality, behavior and language. It often begins between the age of 40 and 65.

Growing Prevalence of Dementia

Growing incidence of dementia among European people are likely to impel the growth of the market.  In 2019, the occurrence of dementia in Europe was roughly 188 per 100,000 population. The growing geriatric population is more susceptible to dementia than younger generation, due to their rising age, which, in turn, is projected to propel the growth of the market. In 2019, about 45 percent of women and 30 percent of men with the age 90 years and above were living with dementia in Europe. Generally, the share of women living with dementia in Europe was much higher when compared to men.

Increasing Number of Clinical Trials

There are large number of clinical studies which are going on for the frontotemporal dementia in the region, which is projected to bolster the growth of the market. There is total 25 clinical studies which are completed in Europe. For instance, in 2019, a clinical trial for the device named transcranial direct current stimulation (tDCS) was completed under the study name of “Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia”.

Recent Developments

• In 2022, AviadoBio, a pioneering, pre-clinical stage, gene therapy company emphasized on developing and delivering transformative medicines for patients with neurodegenerative disorders, announced that both the U.S. Food and Drug Administration (FDA) and the European Commission (EC) have granted orphan designation to AVB-101, a one-time gene therapy for the treatment of frontotemporal dementia (FTD).
• In 2021, Centogene N.V., a commercial-stage company emphasized on producing data-driven insights to diagnose, understand, and treat rare diseases, announced that they have enrolled first patient in the international EFRONT Study, an observational study to know the prevalence of genetic mutations in patients with frontotemporal dementia (FTD).

Download Free Sample Report

Market Segmentation

Europe frontotemporal dementia market is segmented into drug class type, disease type, end user and region. Based on drug class type, the market is divided into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. Based on disease type, the market is bifurcated into frontotemporal dementia, primary progressive aphasia, and others. Based on end user, the market is divided into hospitals & clinics, ambulatory surgery centers, and others. In terms of countries, the market is categorized into France, Germany, United Kingdom, Italy, Spain, Belgium, Netherlands, Switzerland, Poland, and Sweden.

Market Players

GlaxoSmithKline PLC, Eli Lilly Italia S.p.A., Pfizer Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH, Sanofi S.A, Allergen plc, Johnson & Johnson and Viatris Inc are some of the leading companies operating in the Europe Frontotemporal Dementia market.

Report Scope:

In this report, Europe frontotemporal dementia market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Europe Frontotemporal Dementia Market, By Drug Class Type:
• Cognitive Enhancers
• Antipsychotics
• Antidepressants
• CNS Stimulants
• Others
• Europe Frontotemporal Dementia Market, By Disease Type:
• Frontotemporal Dementia
• Primary Progressive Aphasia
• Others
• Europe Frontotemporal Dementia Market, By End User:
• Hospitals & Clinics
• Ambulatory Surgery Centers
• Others
• Europe Frontotemporal Dementia Market, By Country:

• France
• Germany
• United Kingdom
• Italy
• Spain
• Belgium
• Netherlands
• Switzerland
• Poland
• Sweden

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Europe frontotemporal dementia market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

• Profit margin analysis in case of direct and indirect sales channel.